Abstract
Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.
| Original language | English |
|---|---|
| Pages (from-to) | 149-161 |
| Number of pages | 13 |
| Journal | Radiology and Oncology |
| Volume | 40 |
| Issue number | 3 |
| Publication status | Published - 2006 |
Fingerprint
Keywords
- Antineoplastic agents - adverse effects - toxicity
- Heart - drug effects
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
The cardiotoxicity of chemotherapy : New prospects for an old problem. / Miolo, GianMaria; La Mura, Nicoletta; Nigri, Paola; Murrone, Antonio; Da Ronch, Laura; Viel, Elda; Veronesi, Andrea; Lestuzzi, Chiara.
In: Radiology and Oncology, Vol. 40, No. 3, 2006, p. 149-161.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The cardiotoxicity of chemotherapy
T2 - New prospects for an old problem
AU - Miolo, GianMaria
AU - La Mura, Nicoletta
AU - Nigri, Paola
AU - Murrone, Antonio
AU - Da Ronch, Laura
AU - Viel, Elda
AU - Veronesi, Andrea
AU - Lestuzzi, Chiara
PY - 2006
Y1 - 2006
N2 - Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.
AB - Background. Cardiotoxicity caused by chemotherapy, with its diverse early and late presentations, can hamper potentially curative or palliative treatments. The drugs most often linked to cardiotoxicity include anthracyclines, trastuzumab, 5-fluorouracil and taxanes, but some forms of cardiotoxicity have been described, more or less sporadically, for most antitumour agents. It is likely that the widespread use of the new biological target therapies will lead to the identification of other less known toxic effects. The available data on its incidence and clinical presentation, the pathogenetic mechanisms involved, the diagnosis, prevention and management of cardiac toxicity from chemotherapy are briefly reviewed. Conclusions. The identification of novel molecular targets will increase the number of drugs available for the treatment of neoplastic disease. It will be important to evaluate the side effects related to treatment, particularly in organs with a limited regenerative capability such as the heart. Further studies will therefore be necessary.
KW - Antineoplastic agents - adverse effects - toxicity
KW - Heart - drug effects
UR - http://www.scopus.com/inward/record.url?scp=33750087273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750087273&partnerID=8YFLogxK
M3 - Article
VL - 40
SP - 149
EP - 161
JO - Radiology and Oncology
JF - Radiology and Oncology
SN - 1318-2099
IS - 3
ER -